- In patients with myeloma, high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) demonstrated high-level, but limited-duration, response.
- Treatment-associated toxicities and treatment-related mortality limit applicability of the regimen to those bridging to transplantation or novel therapies in the absence of an alternative approach.
Why this matters
- Refractory patients in this setting have limited treatment options in later stages.
- Analysis of mCBAD in 140 patients with newly diagnosed multiple myeloma (NDMM), relapsed/refractory (R/R) MM, and plasma cell leukemia (PCL).
- Funding: MD Anderson Cancer Center.
- Overall response rate:
- R/R MM (n=116): 85% overall response rate (ORR); 7% complete remission (CR); 18% very good partial response (VGPR).
- PCL (n=11): 100% ORR; 10% CR; 20% VGPR.
- NDMM (n=13): 100% ORR; 23% CR; 23% VGPR.
- Median PFS:
- NDMM: 19.61 months (95% CI, 5.26-NA).
- R/R MM: 4.64 (95% CI, 3.75-6.73) months.
- PCL: 7.56 months (95% CI, 4.7-NA).
- 11.48 (95% CI, 7.52-15.9) months median PFS in the 36.2% of patients who used mCBAD as a bridge to autologous hematopoietic stem cell transplantation (auto-HSCT) vs 3.19 (95% CI, 2.4-3.75) months in those who did not.
- Treatment-related mortality:
- NDMM: 0%.
- R/R MM: 8%.
- PCL: 9%.
- Retrospective data.